VI Department of Orthopaedic and Traumatology, Istituto Ortopedico Rizzoli, University of Bologna, Via GC Pupilli 1, 40136 Bologna, Italy.
Clin Orthop Relat Res. 2009 Dec;467(12):3307-20. doi: 10.1007/s11999-009-0885-8. Epub 2009 May 16.
The ideal treatment of osteochondral lesions is debatable. Although autologous chondrocyte implantation provides pain relief, the need for two operations and high costs has prompted a search for alternatives. Bone marrow-derived cells may represent the future in osteochondral repair. Using a device to concentrate bone marrow-derived cells and collagen powder or hyaluronic acid membrane as scaffolds for cell support and platelet gel, a one-step arthroscopic technique was developed for cartilage repair. We performed an in vitro preclinical study to verify the capability of bone marrow-derived cells to differentiate into chondrogenic and osteogenic lineages and to be supported onto scaffolds. In a prospective clinical study, we investigated the ability of this technique to repair talar osteochondral lesions in 48 patients. Minimum followup was 24 months (mean, 29 months; range, 24-35 months). Clinical results were evaluated using the American Orthopaedic Foot and Ankle Society (AOFAS) score and the influence of scaffold type, lesion area, previous surgeries, and lesion depth was considered. MRI and histologic evaluation were performed. The AOFAS score improved from 64.4 +/- 14.5 to 91.4 +/- 7.7. Histologic evaluation showed regenerated tissue in various degrees of remodeling although none showed entirely hyaline cartilage. These data suggest the one-step technique is an alternative for cartilage repair, permitting improved functional scores and overcoming the drawbacks of previous techniques.
Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
骨软骨病变的理想治疗方法仍存在争议。虽然自体软骨细胞移植可缓解疼痛,但需要进行两次手术且费用高昂,这促使人们寻求替代方法。骨髓来源的细胞可能是骨软骨修复的未来。我们使用一种设备浓缩骨髓来源的细胞和胶原粉末或透明质酸膜作为细胞支持和血小板凝胶的支架,开发了一种用于软骨修复的一步关节镜技术。我们进行了一项体外临床前研究,以验证骨髓来源的细胞分化为软骨和成骨谱系的能力,并支持在支架上。在一项前瞻性临床研究中,我们调查了该技术修复 48 例距骨骨软骨病变的能力。最低随访时间为 24 个月(平均 29 个月;范围,24-35 个月)。使用美国矫形足踝协会(AOFAS)评分评估临床结果,并考虑支架类型、病变面积、既往手术和病变深度的影响。进行了 MRI 和组织学评估。AOFAS 评分从 64.4 +/- 14.5 提高到 91.4 +/- 7.7。组织学评估显示,再生组织有不同程度的重塑,但没有完全表现为透明软骨。这些数据表明,一步技术是软骨修复的一种替代方法,可以提高功能评分,并克服先前技术的缺点。
IV 级,治疗研究。有关证据水平的完整描述,请参见作者指南。